128 related articles for article (PubMed ID: 32186773)
1. Growth inhibitory role of the p53 activator SCH 529074 in non‑small cell lung cancer cells expressing mutant p53.
Nenkov M; Ma Y; Haase D; Zhou Z; Li Y; Petersen I; Lu G; Chen Y
Oncol Rep; 2020 Jun; 43(6):2073-2082. PubMed ID: 32186773
[TBL] [Abstract][Full Text] [Related]
2. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
[TBL] [Abstract][Full Text] [Related]
3. Chloroquine induces transitory attenuation of proliferation of human lung cancer cells through regulation of mutant P53 and YAP.
Saini H; Choudhary M; Sharma H; Chowdhury S; Mukherjee S; Chowdhury R
Mol Biol Rep; 2023 Feb; 50(2):1045-1058. PubMed ID: 36385665
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous nuclear ribonucleoprotein A2/B1 regulates the ERK and p53/HDM2 signaling pathways to promote the survival, proliferation and migration of non‑small cell lung cancer cells.
Kim MK; Choi MJ; Lee HM; Choi HS; Park YK; Ryu CJ
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34109989
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
8. Traditional Chinese medicine Ze-Qi-Tang formula inhibit growth of non-small-cell lung cancer cells through the p53 pathway.
Xu Z; Zhang F; Zhu Y; Liu F; Chen X; Wei L; Zhang N; Zhou Q; Zhong H; Yao C; Zhu X; Gong C; Zhu S; Zou C
J Ethnopharmacol; 2019 Apr; 234():180-188. PubMed ID: 30660711
[TBL] [Abstract][Full Text] [Related]
9. Calcein-acetoxymethy ester enhances the antitumor effects of doxorubicin in nonsmall cell lung cancer by regulating the TopBP1/p53RR pathway.
Lv Y; Liu R; Xie S; Zheng X; Mao J; Cai Y; Chen W
Anticancer Drugs; 2017 Sep; 28(8):861-868. PubMed ID: 28628491
[TBL] [Abstract][Full Text] [Related]
10. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
Wang MC; Liang X; Liu ZY; Cui J; Liu Y; Jing L; Jiang LL; Ma JQ; Han LL; Guo QQ; Yang CC; Wang J; Wu T; Nan KJ; Yao Y
Oncol Rep; 2015 Jan; 33(1):239-49. PubMed ID: 25370413
[TBL] [Abstract][Full Text] [Related]
11. Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.
Tang MC; Wu MY; Hwang MH; Chang YT; Huang HJ; Lin AM; Yang JC
PLoS One; 2015; 10(3):e0119135. PubMed ID: 25807554
[TBL] [Abstract][Full Text] [Related]
12. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
[TBL] [Abstract][Full Text] [Related]
13. Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest.
Kriegs M; Gurtner K; Can Y; Brammer I; Rieckmann T; Oertel R; Wysocki M; Dorniok F; Gal A; Grob TJ; Laban S; Kasten-Pisula U; Petersen C; Baumann M; Krause M; Dikomey E
Radiother Oncol; 2015 Apr; 115(1):120-7. PubMed ID: 25796091
[TBL] [Abstract][Full Text] [Related]
14. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
[TBL] [Abstract][Full Text] [Related]
15. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib.
Zou Y; Ling YH; Sironi J; Schwartz EL; Perez-Soler R; Piperdi B
J Thorac Oncol; 2013 Jun; 8(6):693-702. PubMed ID: 23575415
[TBL] [Abstract][Full Text] [Related]
16. A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment.
Siebring-van Olst E; Blijlevens M; de Menezes RX; van der Meulen-Muileman IH; Smit EF; van Beusechem VW
Mol Oncol; 2017 May; 11(5):534-551. PubMed ID: 28296343
[TBL] [Abstract][Full Text] [Related]
17. Bergapten induces G1 arrest of non‑small cell lung cancer cells, associated with the p53‑mediated cascade.
Chiang SR; Lin CS; Lin HH; Shieh PC; Kao SH
Mol Med Rep; 2019 Mar; 19(3):1972-1978. PubMed ID: 30628674
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
Feng FF; Cheng P; Sun C; Wang H; Wang W
Chin J Nat Med; 2019 Oct; 17(10):768-777. PubMed ID: 31703757
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of WRAP53 transcript variants on non-small cell lung cancer cell behaviors.
Zhu Y; Sun W; Jiang X; Bai R; Luo Y; Gao Y; Li S; Huang Z; Gong Y; Xie C
PLoS One; 2023; 18(1):e0281132. PubMed ID: 36706151
[TBL] [Abstract][Full Text] [Related]
20. Enhanced anticancer effects of Scutellaria barbata D. Don in combination with traditional Chinese medicine components on non-small cell lung cancer cells.
Wang Q; Acharya N; Liu Z; Zhou X; Cromie M; Zhu J; Gao W
J Ethnopharmacol; 2018 May; 217():140-151. PubMed ID: 29458146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
